How to appeal a Blue Cross Blue Shield of Michigan pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Michigan-specific note: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.

What Blue Cross Blue Shield of Michigan's policy requires for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Cited policy: Anthem clinical guideline Growth Hormone + BCBS Medical Policy on Somatropin (mirrors PES Grimberg HRP 2016)

PES Pediatric GH Use Recommendations (Grimberg Horm Res Paediatr 2016): GHD requires height <=-2.25 SD AND HV <-1 SD AND IGF-1 / IGFBP-3 low AND peak GH <10 ng/mL on 2 provocative stimuli (insulin tolerance, arginine, clonidine, glucagon). ISS criteria + Turner / Noonan / SGA / SHOX / PWS specific criteria.

How Blue Cross Blue Shield of Michigan denies pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology — and how to counter it

Where Blue Cross Blue Shield of Michigan pushes back: 1) Single GH stim test not adequate; 2) Bone age + IGF-1 not documented; 3) ISS 'not medically necessary'; 4) Dose questioned.

Counter-arguments that hold up: Cite PES Grimberg HRP 2016. Submit growth chart with height/velocity SDs over time, bone age (Greulich-Pyle), IGF-1 + IGFBP-3, MRI brain to rule out hypothalamic-pituitary lesion, two GH stim tests with peak. For Turner: karyotype 45,X. For SGA: birth weight/length <-2 SD with no catch-up by age 4. For SHOX: SHOX gene mutation. For Noonan: PTPN11 / SOS1. Peds endo prescribing.

What Blue Cross Blue Shield of Michigan typically denies for pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology

Across Blue Cross Blue Shield of Michigan's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology, expect:

• Step therapy via OptumRx (PBM since 2024)
• Site-of-care reductions for infusions
• Behavioral health prior auth
• OON balance bill disputes

Treatments most often denied in this category

These are the pediatric subspecialty — cardiology, gi, pulmonology, rheumatology, endocrinology, neurology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Peds congenital heart surgery
• Kawasaki workup + IVIG
• Pediatric ECMO
• Peds EoE workup + therapy
• Peds IBD biologic
• Peds asthma biologic / admission

How to submit the appeal to Blue Cross Blue Shield of Michigan

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Michigan cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Michigan's portal (members: https://www.bcbsm.com ; providers: https://providers.bcbsm.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Michigan's prior-authorization criteria by drug: Blue Cross Blue Shield of Michigan PA criteria on ApprovalHelp.